The UAB-led clinical trial intends to provide multiple myeloma patients a treatment plan that eradicates their disease and enables them to live a life without ongoing treatment.
A new model for improving how clinical trials are developed and conducted by bringing together academic cancer experts and pharmaceutical companies is being tested by research experts at The University of Texas MD Anderson Cancer Center.
The VF produced a new video called "Connect the Dots" especially for Vasculitis Awareness Month 2018. The short, animated video reminds medical professionals to "Think Vasculitis" when they have a patient exhibiting a cluster of chronic, unremarkable symptoms that don't respond to traditional treatment.
• This study was the first to test a form of intermittent fasting, known as early time-restricted feeding, in humans.
• The study shows for the first time in humans that the benefits of intermittent fasting are not due solely to eating less.
• Practicing intermittent fasting has intrinsic benefits regardless of what you eat.
A Johns Hopkins study found that physicians who use stigmatizing language in their patients’ medical records may affect the care those patients get for years to come.
TAMPA, Fla. – Chimeric Antigen Receptor T-cell therapy, also known as CAR T therapy, was named the biggest research breakthrough of 2017 by the American Society of Clinical Oncology. The personal gene therapy utilizes a patient’s own immune cells to fight cancer. The Food and Drug Administration has approved CAR T therapy products for adults with diffuse large B-cell lymphoma and pediatric and young adults suffering from acute lymphoblastic leukemia.
New research from the Stowers Institute for Medical Research reveals that a DNA regulatory element within the Hoxb cluster globally mediates signals to the majority of Hoxb genes to control their expression in blood-forming stem cells.
NCCN and MPN Research Foundation present Know What Your Doctors Know: Myeloproliferative Neoplasms (MPN), a free webinar for experts to provide information and answer questions on diagnosis and treatment options.
The VF announces the launch of Vasculitis Awareness Month 2018 that runs through May. The VF is holding special webinars, providing educational materials, and featuring other resources to inform both the patient and medical communities about autoimmune vasculitis.
Researchers at Memorial Sloan Kettering (MSK) report that firefighters at the World Trade Center (WTC) scene in September 2001 were nearly twice as likely as the general population to have a multiple myeloma precursor condition called monoclonal gammopathy of undetermined significance (MGUS).
The addition of a nurse-led intervention for hypertension management to health insurance coverage was more effective in lowering blood pressure (HPB) than the provision of health insurance alone in the Sub-Saharan country of Ghana, a region of Africa where HPB is rampant, according to a study publishing online on May 1 in the journal PLOS Medicine.
Penn Medicine researchers may have found the reason why some patients with advanced chronic lymphocytic leukemia (CLL) don’t respond to chimeric antigen receptor (CAR) T cell therapy, and the answer is tied to how primed patients’ immune systems are before the therapy is administered.
Notre Dame researchers found that this communication varies across the colony and suggest that this bacterium may develop protective behaviors that contribute to its ability to tolerate some antibiotics.
Physician scientist Christopher Seymour talks about his experience treating sepsis patients and his new study indicating that quicker treatment improves survival odds.
Researchers from the Saint Louis University School of Medicine have discovered why many multiple myeloma patients experience severe pain when treated with the anticancer drug bortezomib. The study, which will be published April 27 in the Journal of Experimental Medicine, suggests that a drug already approved to treat multiple sclerosis could mitigate this effect, allowing myeloma patients to successfully complete their treatment and relieving the pain of myeloma survivors.
A study in today’s issue of JAMA Oncology reports that New York City firefighters exposed to the 9/11 World Trade Center disaster site face an increased risk for developing myeloma precursor disease (MGUS), which can lead to the blood cancer multiple myeloma. The study was conducted by researchers at Albert Einstein College of Medicine, Montefiore Health System, the Fire Department of the City of New York (FDNY) and Memorial Sloan Kettering Cancer Center.
A research team from Queen’s University Belfast, in collaboration with an international team of experts, have made ground-breaking insights into how inflammatory diseases work.
Doctors at the University of Illinois Hospital have cured seven adult patients of sickle cell disease, an inherited blood disorder primarily affecting the black community, using stem cells from donors previously thought to be incompatible, thanks to a new transplant treatment protocol.
A new study at Washington University School of Medicine in St. Louis shows an investigational drug prevents graft-versus-host disease, a dangerous side effect of stem cell transplantation.
Investigators at Rutgers Cancer Institute have discovered that some mutations detected in comprehensive, clinical genome sequencing of patients with solid tumors do not originate from cancer cells, but arise from mutated hematopoietic cells that infiltrate the tumor microenvironment. The findings, they say, have direct implications for cancer patients, specifically in accurately interpreting their molecular testing results and ensuring that treatment is focused on somatic tumor-specific mutations.
A new University of Kansas research effort featured in the current edition of Integrative Biology has resulted in a low-cost, reliable blood test that uses a small plastic chip about the size of a credit card that can deliver the same diagnostic information as a bone biopsy — but using a simple blood draw instead.
Interim results of clinical trials by investigators at UCSF Benioff Children’s Hospital Oakland and Ann and Robert H. Lurie Children’s Hospital of Chicago reveal that a majority of the 22 patients in two Phase 1/2 studies followed for two years or longer remained free from transfusions.
The results of the trials “Gene Therapy in Patients with Transfusion-Dependentβ-Thalassemia,” are published today in the New England Journal of Medicine (NEJM). The results are from two separate, two-year clinical studies using LentiGlobin® gene therapy to stop or reduce chronic blood transfusions in patients with transfusion-dependent β-thalassemia (TDT).
Despite universal newborn screening that detects the presence of sickle cell trait (SCT), only 16 percent of Americans with SCT know their status. To address this issue, in Ohio, in-person education is offered to caregivers of referred infants with SCT.
Students develop a blood-clotting “super gel” that can be injected through a catheter but is hyper-absorbent enough to then swell with blood, blocking further bleeding.
Atlantic Health System’s new Atlantic HPV Center is one of a small number of research centers in the nation to begin a study to determine whether an innovative combination of immuno-oncology treatments is safe, shows preliminary efficacy and provokes an anticancer immune system response in patients with recurrent or metastatic human papilloma virus (HPV) associated head and neck squamous cancer.
In a study published online today in Science Translational Medicine, Albert Einstein College of Medicine researchers report that an experimental peptide (small protein) drug shows promise against the often-lethal cancer acute myeloid leukemia (AML) and describe how the drug works at the molecular level. The findings have led to a Phase I/II clinical trial for patients with advanced AML and advanced myelodysplastic syndrome (MDS), now underway at Montefiore Health System.
Across the world, over 200 million cases of malaria and nearly 500,000 deaths from the disease occur annually—more than 90 percent of which happen in Africa. Children in Africa can be diagnosed with malaria two or three times a year, a rate that decreases as they become older and develop immunity. But the way children generate and maintain this immunity remains a mystery. Katherine Dobbs, MD, a tropical infectious diseases and malaria researcher, is conducting research in Kenya to find answers by studying white blood cells important to innate immunity, the body’s “first response” to infection.
New research out of Roswell Park Comprehensive Cancer Center and The Ohio State University has identified rare variants in a number of novel genes that may help improve risk prediction and prognosis for patients undergoing BMT.
Researchers at Université de Montréal and the research centres of the CHUM and CHU Sainte-Justine are banding together to conquer this rare orphan pediatric disease. They have recently proven what scientists had already suspected: the disease is autoimmune, which means that it attacks patients using their own immune system.
Beta blockers have become a prescription drug staple for recovering heart attack patients. However, these blood pressure-reducing medications cannot be tolerated by many patients who are at higher risk for developing cardiovascular disease, including those with chronic obstructive pulmonary disease (COPD) and asthma, the elderly, and diabetics. As seen in the March 26 issue of Thyroid, researchers at New York Institute of Technology College of Osteopathic Medicine (NYITCOM) now pose a new treatment for patients with beta blocker intolerance: thyroid hormone therapy.
• The CDC reports that about 3,200 cases of oropharyngeal cancers were found in women last year and about 13,000 in men in the United States.
• Cancers of the throat can masquerade as many things, such as ear pain, sore throat, hoarse voice, difficulty swallowing, coughing up blood or loose teeth.
Head and neck cancer experts from UC San Diego Health define head and neck cancer and treatment options and explain risk factors, including smoking and HPV, as well as screening and prevention.
Cells acquire distinct fates and functions during development. A study from the IMBA reveals a new mechanism of cell fate specification involving the regulation of cell metabolism.
A new study suggests that resistance exercise may improve indicators of type 2 diabetes by increasing expression of a protein that regulates blood sugar (glucose) absorption in the body.
Leading cancer researchers, Alex Huang MD, PhD, and Yamilet Huerta, MD have been awarded $186,405 in grants from the St. Baldrick’s Foundation to conduct pediatric cancer research.
Chemotherapy agents have been associated with neurocognitive side effects in young leukemia survivors. Now St. Jude Children’s Research Hospital scientists have evidence the disease and genetics might also play a role.
The Barth Syndrome Foundation recently announced awardees from its 2017 grant cycle. Miriam Greenberg, Ph.D., professor of biological sciences in the College of Liberal Arts and Sciences at Wayne State University and a resident of Ann Arbor, Michigan, received a one-year, $50,000 grant for the project, “Cardiolipin activates pyruvate dehydrogenase (PDH) – a potential new target for treatment of Barth syndrome.”
UCLA scientists discovered higher levels of a protein called humanin in the placenta tissue of women who give birth to severely underweight infants. The researchers suspect that humanin rises to protect the fetus during placenta failure.
The Pulmonary Hypertension Association has designated the Pulmonary Hypertension Center at the University of Virginia Heart and Vascular Center as a Center of Comprehensive Care.
Working with cells that line the innermost layer of the blood vessels, Johns Hopkins investigators say they have made a leap forward in understanding the underlying biology behind pulmonary hypertension, a dangerous type of high blood pressure in lungs that ultimately leads to right heart failure and death.
Childhood lead exposure was a problem in Flint long before the water crisis, but young children’s exposure to the toxin has been steadily declining since 2006.
University of Chicago researchers have begun to unravel the role of RNA epigenetics and chromatin structure in regulation of 5-azacytidine (5-AZA), a well-known DNA hypomethylating agent in MDS and AML. The finding may lead to novel strategies, as well as guidance from clinical biomarkers.
The nation’s overall cardiovascular health worsened from 1988 to 2014, with disparities among racial and ethnic groups dropping slightly. But the reduction in disparities was due to worsening health among whites — not improvements among African-Americans and Mexican-Americans, a new UCLA-led study suggests. “The reason for the reduction in disparities was unexpected,” said lead author Dr.